POM POM
Company Profile ↓Company Overview
POM (POM) is a publicly traded company listed on with a market capitalization of $16.23M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 46.8%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 105.2%.
Revenue has grown at a 17.7% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $399.91M (+16.7% YoY); net profit $-212.58M.
- Trailing 12 Months Year-on-year growth — revenue +16.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 17.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 17.71% |
| 1 Year: | 16.74% |
Stock Price Performance
| 1 Year: | -99.03% |
| 6 Months: | -83.38% |
| 3 Months: | -90.15% |
| 1 Month: | -53.93% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)34.47 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 46.8%.
- Healthy ROCE of 105.2%.
- Compounding revenue at 17.7% over 5 years.
CONS
- Trading 99.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 245.22M | 304.85M | 342.56M | 399.91M |
| Cost of Revenue | 190.36M | 266.13M | 294.86M | 347.63M |
| Gross Profit | 54.86M | 38.72M | 47.69M | 52.28M |
| Operating Expenses | 58.18M | 59.04M | 71.06M | 168.66M |
| Operating Income | -3.31M | -20.32M | -23.36M | -116.37M |
| EBITDA | -3.81M | -22.99M | -24.27M | -117.90M |
| Interest Expense | 16.02M | 13.85M | 12.96M | 12.89M |
| Pretax Income | -19.83M | -36.95M | -37.37M | -130.93M |
| Tax Provision | 0 | 0 | 0 | 375 |
| Net Income | -125.51M | -145.39M | -143.36M | -212.58M |
| Diluted EPS | -19.07 | -22.10 | -21.79 | -3.66 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 48.62M | 66.31M | 46.23M | 107.56M |
| Current Assets | - | 47.74M | 59.42M | 37.50M | 104.97M |
| Cash & Equivalents | - | 2.49M | 6.72M | 7.65M | 9.58M |
| Inventory | - | 8.20M | 12.69M | 9.17M | 8.28M |
| Receivables | - | 28.27M | 28.64M | 8.80M | 19.27M |
| Total Liabilities | - | 1.95B | 2.03B | 2.14B | 588.85M |
| Current Liabilities | - | 143.61M | 172.00M | 179.15M | 218.17M |
| Long Term Debt | - | 318.93M | 355.40M | 365.09M | 369.39M |
| Total Debt | - | 361.24M | 413.29M | 441.10M | 454.94M |
| Total Equity | - | -1.97B | -2.12B | -2.26B | -453.97M |
| Shares Outstanding | - | 19.74M | 19.74M | 19.74M | 23.18M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -22.02M | -45.80M | -16.13M | -148.48M |
| Investing Cash Flow | - | 0 | -111.89K | -33.37K | -1.61M |
| Financing Cash Flow | - | 22.49M | 50.07M | 17.02M | 153.93M |
| Capital Expenditure | - | - | -111.89K | -37.77K | -1.01M |
| Free Cash Flow | - | -22.02M | -45.91M | -16.17M | -149.49M |
| Net Change in Cash | - | 474.66K | 4.16M | 851.83K | 3.84M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 22.4% | 12.7% | 13.9% | 13.1% |
| Operating Margin % | -1.4% | -6.7% | -6.8% | -29.1% |
| Net Margin % | -51.2% | -47.7% | -41.9% | -53.2% |
| ROE % | 6.4% | 6.9% | 6.3% | 46.8% |
| ROCE % | 3.5% | 19.2% | 17.6% | 105.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for POM
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.02% - Investing.com
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPU3l0dW5sMFVKb21LUElDX1pqZk5wb3p6VWdZWFBEMzUwX0FvX3V2dTFIcHhVdXJVRDc4UUpVV2JRd182dlB4Ui1IRkRGSG1tc1RBcmsydERENk1qNGVzTXRIcnJ0NEpoZTRWT0NqYkp6T0hZdVVvWk1jRzhKeGg2RGxTcEdjclBQb1l2T1…
POMDOCTOR LIMITED SPON ADS EACH REP 3 CL A(R/S) (POM) Revenue Breakdown - Main Composition - Moomoo
<a href="https://news.google.com/rss/articles/CBMiyAJBVV95cUxOdG1SdUdSenV2bE11SXZ2eGdsS3VjMTlvM1BfMVEyenpWelJUek0zeU9sUENxejF4LWVpSmk1OWZYcG9NLTBzNXFsRGluSXAyV042Q3BlMHF1dVE4Rk9YZnJ4bWlfQVc5bk9oQldnUWhTc21YWlVFNzZqdkh0TDBUYnBXY0pSUk5rbXZsMk…
POMDOCTOR LIMITED Announces ADS Ratio Change to Be Effective on June 22, 2026 - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNSTNfd0Y1M3VRT2JZSnU3ZjUxdXpmVFplMVRVZWFwdHY2blJfMEh3WElKZXFTTGNSamlhZkFuVUR4MHdPbGYyR2tkM0VSamFZRTdXdklhRHVsU0hxTm5zeU9YSHd5V3FDcHRHS1VyVGhiaWVXQTZsYjJ1c2hFQ2hDWWJXMHB2UU8wUjZYZm…
POMDOCTOR LIMITED Revenue Breakdown – NASDAQ:POM - TradingView
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTFBLU2wybWhVbXRlVVVYbm00cjlJcDdYWnBKLXdPXzhyb2lkdlluNXRwT1dTVFQ2c05hNDFNQnoyYU02RGRfcjFWQ0h4S0E5ZDJSX1BQREVqbmgtUTlvLXpoRk5mTlRIZUFJeDhUS3hnRXRaVHF0TkE?oc=5" target="_blank">POMDOCTO…
Is POM’s Stock the Next Big Bet? - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTFBUOHpqZUxVM3BsWDBlR2xLajItU01UbnFUMTg5M2JHT2hBbVN0UmJkZVB4dXBSMDZLSl9IMGFlZ0EtZmhxM0dvZjNwSzRmSVVDeDYwN3F3MEtQOXZzSG5MTjdsVDBXOVFteFRnYzdxT2Z6UHl2YnlsUg?oc=5" target="_blank">Is PO…
Should You Buy POM Stock After the PomDoctor IPO? - Barchart.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNWEhyMkxKc2hTQUh4QlJQc0w4dy1fUV9aR2ZGeFp1TXZsR1FJdmFZNnluUXZPNGRrMmZjb290NURxNWNHVVdsUzN4SmJaNTExSU02Ykhna2pHOFN1MzVULTc2TXhKazZObGtfa1QwRDV0dzlGM1p0Y09UWGppek9WQnR0UzdCRldqVUZSVF…
POM — Frequently Asked Questions
What is the current share price of POM?
As of 2026-08-05 17:25 PDT, POM trades at $0.70 on NASDAQ/NYSE. Its 52-week range is $0.55 to $109.62.
What is the market capitalisation of POM?
POM has a market capitalisation of $16.23M on NASDAQ/NYSE.
What is the P/E ratio of POM?
POM trades at a trailing price-to-earnings (P/E) ratio of -0.19. Its price-to-book (P/B) ratio is -0.04.
What is the return on equity (ROE) of POM?
POM has a return on equity (ROE) of 46.83%. Its return on capital employed (ROCE) is 105.21%.
Is POM a good stock to buy?
This page provides a data-driven analysis of POM, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.